Skip to main content
OpenTrials
Completed

NCT Number: NCT03321955

Ziconotide as First-Line IDT

The primary objective of this study is to prospectively examine outcomes in 12 patients using ziconotide Intrathecal Drug Therapy(IDT) as first-line monotherapy with the use of an algorithm of slow titration for dosing. The use of Prialt has demonstrated fewer and less serious associated adverse effects as compared to IDT morphine, especially when titrated slowly. We will use an average Numerical Rating Scale as our primary outcome and the Oswestry Disability Index(ODI), Beck Depression Inventory (BDI), Pain Catastrophizing Scale (PCS), Clinical Global Impression of Change Scale including binary satisfaction measures(CGIC), Lawton-Brody Instrumental Activities of Daily Living(IADL) and Short Form-36 as secondary outcome measures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuropathic Pain Nervous System Diseases Neuralgia Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Albany Medical College

Albany, New York, 12208, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be eligible for implantation of an intrathecal analgesia programmable pump system using ziconotide IT.
  • Must be 18 years of age or older for all points of data collection.
  • Must be diagnosed with neuropathic pain secondary to a clear etiology. Acceptable etiologies including but not limited to diabetic neuropathy, small fiber neuropathy, and post herpetic neuropathy.

Exclusion criteria

  • Must not have or been previously implanted with a programmable pump system.
  • Untreated mental illness including depression or anxiety determined by preoperative psychological evaluation.
  • Active substance abuse determined by preoperative urine drug screen.
  • Unwillingness to decrease oral medications at screening.
  • Any prior use of intrathecal analgesia besides trialing

Treatment and study plan

Ziconotide 100 MCG(microgram)/ML Intrathecal Solution

Drug

Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.

quantitative sensory testing

Diagnostic Test

Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,

Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor

Diagnostic Test

Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.

Primary outcomes

  1. Numerical Rating Scale (NRS)

    Time frame: Baseline, 3, 4, 6, 8, 9, 10, 12 week and 4, 5, 6 and 12 months

    This scale allows the subject to quantify their pain numerically, with 10 being the worst pain imaginable. This scale describe subject reported pain at its worst and best in the week prior to reporting, as well as total pain on average, and at the time of documentation. The mean of these scores will be used as the primary outcome. This scale also includes a question of subject experienced global improvement in which the patient is asked to quantify their overall change in pain with 0 being no change and 10 being completely changed. Using the NRS we will calculate a responder rate, assessing percentage of patients with a 50% response in NRS

Secondary outcomes

  1. Oswestry Disability Index Scale

    Time frame: Baseline, 12 weeks, 6 month, 12 month

    Comprises 11 sections, this survey asks the patient to indicate the degree to which they have difficulty in daily life relating to pain.

  2. SF (Short Form) - 36

    Time frame: Baseline, 12 weeks, 6 month

    This scale utilizes 36 questions to determine overall quality of life in patients by discussing physical health, emotional health, and social engagement.

  3. IADL(Instrumental Activities of Daily Living)

    Time frame: Baseline, 12 weeks, 6 month, 12 month

    Used to assess complex functional activities of daily living, this scale extrapolates on basic activities such as ability to eat or walk, to include cooking shopping, housekeeping.

  4. Beck Depression Inventory

    Time frame: Baseline, 12 weeks, 6 month, 12 month

    21 question survey pertaining to a patient's severity of depression. Each question is scored for 0 to 3, with 0 indicating no depression and 3 indicating the most severe depression

  5. Pain Catastrophizing Scale

    Time frame: Baseline, 12 weeks, 6 month, 12 month

    This scale separates three types of catastrophizing: rumination, magnification and helplessness. Catastrophic thinking can contribute to the probability that a pain condition will be persistent over tim.

Sponsors and collaborators

Lead sponsor

Albany Medical College

Other

Registry information

Official study title

Prospective Study of Conservative Ziconotide Dosing as a First-Line Intrathecal Drug Therapy for Neuropathic Pain

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Oct 26, 2017
Registry last updated
Jan 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.